A Phase 2 interventional study of Atrasentan and Atrasentan in IgA Nephropathy and Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.
Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 7th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Brazil, China and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8
First in 2018; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 108 across the 14 interventional studies, 300 across the 3 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Glomerulonephritis, IGA by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06797518Novartis PharmaceuticalsStudy to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | 2027-11-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Glomerulonephritis, IGA by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
Patients with biopsy-proven IgAN who were on a background SGLT2i and a maximally tolerated and stable dose of a renin-angiotensin system inhibitor (RASi) [such as angiotensin converting enzyme inhibitor (ACEi) or angiotensin-receptor antagonist (ARB)] as part of standard of care, were randomized to either sequence Atrasentan/Placebo or sequence Placebo/Atrasentan in which they received 0.75 mg atrasentan once daily during one period (period A), complete a 12-week washout period, and then received matching placebo during the other period (period B) as determined by the randomization schema.
Subjects who were not on background SGLT2i therapy would first undergo a run-in period of 8 weeks with an SGLT2i with a 24-hour total urine protein of > 0.85 grams/day at screening prior to the run-in period and have 24-hour total urine protein of > 0.5 grams/day at the end of the run-in period to be eligible for randomization.
Subjects remained on their maximally tolerated and stable dose of RASi and stable dose of SGLT2i therapies for the duration of the study following randomization.
The primary objective of the study was to evaluate the efficacy of atrasentan vs. placebo while on background therapy with SGLT2i.
Inclusion Criteria:
Inclusion Criteria for SGLT2i stable subjects
Inclusion Criteria for Run-In Subjects
Additional Inclusion Criteria for Run-in Subjects at the end of Run-In
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily oral administration of 0.75 mg atrasentan for 12 weeks (Period A) followed by once daily oral administration of placebo for 24 weeks (Period B)
Drug: Atrasentan · Drug: Placebo
Once daily oral administration of placebo for 12 weeks (Period B) followed by once daily oral administration of 0.75 mg atrasentan for 24 weeks (Period A)
Drug: Atrasentan · Drug: Placebo
Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627
Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627
Placebo
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12
Change in proteinuria from Baseline to Week 12 across both periods between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.
Time frame: From Baseline to Week 12
Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2.
Change in proteinuria from Baseline to Week 24 in Treatment Period 2 between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.
Time frame: From Baseline to Week 24 of Treatment Period 2
Number of Subjects With TEAE and TEAESI
Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Adverse Events of Special Interest (TEAESI). Severity assessment of AEs was based on CTCAE (Common Terminology Criteria for Adverse Events).
Time frame: From first dose of study treatment until end of study, up to 60 weeks
Plasma Concentration of Atrasentan
Blood samples were collected for the measurement of plasma concentrations of atrasentan.
Time frame: Treatment Period 1: Pre-dose on Weeks 2, 6 and 12; Treatment Period 2: Pre-dose on Weeks 2, 6, 12 and 24
| Milestone | Sequence Atrasentan/Placebo | Sequence Placebo/Atrasentan |
|---|---|---|
| Started | 27 | 27 |
| Completed treatment period 1 | 27 | 27 |
| Completed washout period | 27 | 27 |
| Completed treatment period 2 | 26 | 26 |
| Intention-to-treat (itt) analysis set | 27 | 27 |
| Safety analysis set | 27 | 27 |
| Pharmacokinetic analysis set | 26 | 27 |
| Completed | 26 | 27 |
| Not completed | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
Change in proteinuria from Baseline to Week 12 across both periods between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.
| percentage change in UPCR | Atrasentan | Placebo |
|---|---|---|
| Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12 | -30.7 (-38.5 to -21.9) | -7.2 (-17.7 to 4.7) |
Change in proteinuria from Baseline to Week 24 in Treatment Period 2 between atrasentan versus placebo. Proteinuria was assessed using the urine protein to creatinine ratio (UPCR) measured from a 24-hour urine collection.
| percentage change in UPCR | Atrasentan Period 2 | Placebo Period 2 |
|---|---|---|
| Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 24 in Treatment Period 2. | -27.0 (-41.0 to -9.8) | -0.9 (-20.6 to 23.7) |
Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Adverse Events of Special Interest (TEAESI). Severity assessment of AEs was based on CTCAE (Common Terminology Criteria for Adverse Events).
| Participants | Atrasentan Period 1 | Placebo Period 1 | Placebo Period 2 | Atrasentan Period 2 |
|---|---|---|---|---|
| Adverse events (AEs) | 19 | 17 | 17 | 16 |
| Treatment-related AEs | 6 | 4 | 3 | 2 |
| Any Moderate or Severe AEs | 7 | 7 | 7 | 7 |
| Treatment-related Moderate or Severe AEs | 1 | 0 | 0 | 1 |
| Severe AEs | 0 | 0 | 0 | 1 |
| Treatment-related Severe AEs | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 1 |
| Treatment-related SAEs | 0 | 0 | 0 | 0 |
| Adverse events of special interest | 6 | 2 | 6 | 4 |
| Treatment-related AEs of special interest | 5 | 1 | 3 | 1 |
| Serious adverse events of special interest | 0 | 0 | 0 | 0 |
Blood samples were collected for the measurement of plasma concentrations of atrasentan.
| ng/mL | Atrasentan Period 1 | Atrasentan Period 2 |
|---|---|---|
| Week 2 - Predose | 1.07 (0.866 to 1.81) | 1.13 (0.579 to 1.53) |
| Week 6 - Predose | 1.41 (1.08 to 2.39) | 1.26 (0.855 to 1.47) |
| Week 12 - Predose | 1.28 (0.846 to 2.19) | 1.17 (0.633 to 1.61) |
| Week 24 - Predose | — | 1.06 (0.547 to 1.38) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days, up to a maximum duration of 60 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Total | 0/54 (0%) | 0/54 (0%) | 1/54 (1.9%) |
| Treatment Period: Atrasentan | 0/27 (0%) | 0/27 (0%) | 11/27 (40.7%) |
| Treatment Period 1: Placebo | 0/27 (0%) | 0/27 (0%) | 8/27 (29.6%) |
| Treatment Period 1 Total | 0/54 (0%) | 0/54 (0%) | 19/54 (35.2%) |
| Washout Period: Atrasentan | 0/27 (0%) | 0/27 (0%) | 7/27 (25.9%) |
| Washout Period: Placebo | 0/27 (0%) | 0/27 (0%) | 3/27 (11.1%) |
| Washout Period Total | 0/54 (0%) | 0/54 (0%) | 10/54 (18.5%) |
| Treatment Period 2: Placebo | 0/27 (0%) | 0/27 (0%) | 13/27 (48.1%) |
| Treatment Period 2: Atrasentan | 0/27 (0%) | 1/27 (3.7%) | 5/27 (18.5%) |
| Treatment Period 2 Total | 0/54 (0%) | 1/54 (1.9%) | 18/54 (33.3%) |
| Follow-up Period: Placebo | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Follow-up Period: Atrasentan | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Follow-up Period: Total | 0/54 (0%) | 0/54 (0%) | 0/54 (0%) |
| Event | Run-in Total | Treatment Period: Atrasentan | Treatment Period 1: Placebo | Treatment Period 1 Total | Washout Period: Atrasentan | Washout Period: Placebo | Washout Period Total | Treatment Period 2: Placebo | Treatment Period 2: Atrasentan | Treatment Period 2 Total | Follow-up Period: Placebo | Follow-up Period: Atrasentan | Follow-up Period: Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytomegalovirus infectionInfections and infestations | 0/54 | 0/27 | 0/27 | 0/54 | 0/27 | 0/27 | 0/54 | 0/27 | 1/27 | 1/54 | 0/27 | 0/27 | 0/54 |
| Event | Run-in Total | Treatment Period: Atrasentan | Treatment Period 1: Placebo | Treatment Period 1 Total | Washout Period: Atrasentan | Washout Period: Placebo | Washout Period Total | Treatment Period 2: Placebo | Treatment Period 2: Atrasentan | Treatment Period 2 Total | Follow-up Period: Placebo | Follow-up Period: Atrasentan | Follow-up Period: Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/54 | 4/27 | 0/27 | 4/54 | 3/27 | 1/27 | 4/54 | 3/27 | 2/27 | 5/54 | 0/27 | 0/27 | 0/54 |
| Fluid retentionMetabolism and nutrition disorders | 0/54 | 3/27 | 0/27 | 3/54 | 0/27 | 0/27 | 0/54 | 3/27 | 1/27 | 4/54 | 0/27 | 0/27 | 0/54 |
| HypotensionVascular disorders | 0/54 | 1/27 | 1/27 | 2/54 | 1/27 | 0/27 | 1/54 | 3/27 | 1/27 | 4/54 | 0/27 | 0/27 | 0/54 |
| GastroenteritisInfections and infestations | 0/54 | 1/27 | 1/27 | 2/54 | 0/27 | 1/27 | 1/54 | 2/27 | 0/27 | 2/54 | 0/27 | 0/27 | 0/54 |
| InfluenzaInfections and infestations | 0/54 | 2/27 | 1/27 | 3/54 | 0/27 | 0/27 | 0/54 | 1/27 | 0/27 | 1/54 | 0/27 | 0/27 | 0/54 |
| NasopharyngitisInfections and infestations | 0/54 | 0/27 | 2/27 | 2/54 | 1/27 | 0/27 | 1/54 | 2/27 | 1/27 | 3/54 | 0/27 | 0/27 | 0/54 |
| Viral infectionInfections and infestations | 0/54 | 2/27 | 0/27 | 2/54 | 0/27 | 0/27 | 0/54 | 0/27 | 0/27 | 0/54 | 0/27 | 0/27 | 0/54 |
| Back painMusculoskeletal and connective tissue disorders | 0/54 | 0/27 | 2/27 | 2/54 | 2/27 | 0/27 | 2/54 | 0/27 | 2/27 | 2/54 | 0/27 | 0/27 | 0/54 |
| DizzinessNervous system disorders | 0/54 | 2/27 | 0/27 | 2/54 | 0/27 | 0/27 | 0/54 | 0/27 | 1/27 | 1/54 | 0/27 | 0/27 | 0/54 |
| HeadacheNervous system disorders | 0/54 | 0/27 | 1/27 | 1/54 | 0/27 | 0/27 | 0/54 | 2/27 | 2/27 | 4/54 | 0/27 | 0/27 | 0/54 |
| Age, Categorical(Participants) | Sequence Atrasentan/Placebo | Sequence Placebo/Atrasentan | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 26 | 49 |
| >=65 years | 4 | 1 | 5 |
| Age, Continuous(years) | Sequence Atrasentan/Placebo | Sequence Placebo/Atrasentan | Total |
|---|---|---|---|
| Mean | 52.2 ± 11.43 | 43.2 ± 10.66 | 47.7 ± 11.85 |
| Sex: Female, Male(Participants) | Sequence Atrasentan/Placebo | Sequence Placebo/Atrasentan | Total |
|---|---|---|---|
| Female | 12 | 11 | 23 |
| Male | 15 | 16 | 31 |
| Race/Ethnicity, Customized(Participants) | Sequence Atrasentan/Placebo | Sequence Placebo/Atrasentan | Total |
|---|---|---|---|
| Asian | 10 | 5 | 15 |
| White | 15 | 20 | 35 |
| Multiple | 1 | 2 | 3 |
| Not reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Ran from Jul 2023 to primary completion in Jun 2025, 23 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atrasentan